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Physiological circadian rhythms are orchestrated by the hypothalamic 
suprachiasmatic nucleus (SCN). The activity of SCN cells is synchronised by environmental 
signals, including light information from retinal ganglion cells (RGCs). We recently described 
a population of vasopressin-expressing RGCs (VP-RGC) which send axonal projections to 
the SCN. To determine how these VP-RGCs influence the activity of cells in the SCN, we 
used optogenetic tools to specifically activate their axon terminals within the SCN. Rats were 
intravitreally injected with a recombinant adeno-associated virus (rAAV) to express the 
channelrhodopsin-2 and the red fluorescent protein mCherry under the vasopressin promoter 
(VP-ChR2mCherry). In vitro recordings in acute brain slices showed that approximately 30% 
of ventrolateral SCN cells responded to optogenetic stimulation with an increase in firing rate 
that progressively increased during the first 200 s of stimulation and which persisted after the 
end of stimulation. Finally, application of a vasopressin V1A receptor antagonist dampened 
the response to optogenetic stimulation. Our data suggest that optogenetic stimulation of VP-





 In all animals, the transition between night and day engages a host of physiological 
and behavioural rhythms. A subset of retinal ganglion cells (RGCs) that express melanopsin 
detect the ambient light level, and they project to the suprachiasmatic nucleus (SCN) of the 
hypothalamus to entrain circadian rhythms that are generated within the SCN (1-4). We have 
recently shown that a subpopulation of these RGCs express the neuropeptide vasopressin 
(VP-RGCs). The electrical activity of VP-RGCs is stimulated by light, and vasopressin 
concentrations in the SCN, measured by microdialysis in vivo, increase following light 
exposure (5). 
 Vasopressin is also expressed in many neurons of the dorsomedial SCN shell, and 
these have a critical role in maintaining circadian rhythms (6). SCN vasopressin 
concentrations and the expression of vasopressin V1A receptors in the SCN are under 
circadian control (7, 8) and transgenic mice deficient in vasopressin V1A receptors show 
dampened circadian rhythms in the absence of light-cues (8). Additionally, infusion of 
vasopressin V1 antagonists into the SCN speeds up re-entrainment of mice to a new light 
dark cycle when the light phase is shifted experimentally (9).  
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 The vasopressin cells in the SCN shell are not direct recipients of signals from the VP-
RGCs; the projections from the retina innervate just the ventrolateral ‘core’ of the SCN, which 
contains neurones expressing other neuropeptides, including vasoactive intestinal peptide 
(VIP) and gastrin-releasing peptide (GRP) (10). Light exposure and stimulation of the retino-
hypothalamic tract increases the electrical activity of ventrolateral SCN core neurons in vivo, 
and these responses are attenuated by the local application of a vasopressin V1A receptor 
antagonist (5). Together these studies suggest that activation of VP-RGCs results in 
vasopressin release in the SCN, which in turn influences the electrical activity of SCN core 
neurons. 
 However, the source from which vasopressin is secreted into the SCN following light 
exposure is unclear. Vasopressin could either be secreted from VP-RGC axon terminals in 
the SCN core or from the dendrites of vasopressin neurons in the SCN shell. Here, we used 
optogenetics to selectively activate VP-RGC axons in the SCN, measured the influence of 
this on the electrical activity of SCN core neurons, and investigated the effects of a V1a 






All experimental procedures were approved by a local ethical committee and carried 
out under the UK Home Office Animals (Scientific Procedures) Act 1986 by trained personal 
licence holders. Experiments were performed on a homozygous transgenic rat-line 
expressing an arginine vasopressin enhanced green fluorescent protein (eGFP) fusion gene 
(11). Male and female rats of ~7-8 weeks old were used. Rats were housed in same-sex 
groups in controlled conditions (20-22°C) in a normal 12h dark-light cycle (lights on at 07.00) 
or shifted dark-light cycle (lights on at 11.00), with ad lib access to food and water. Rats were 
housed in the shifted dark-light cycle for at least two weeks before being used for in vitro 
electrophysiology.  
 
Cloning of rAAV Vectors - Production of rAAVs 
rAAV (serotype 1/2) carrying a conserved 1.9kb AVP promoter and cDNA of ChR2 
(generously provided by Scott Sternson, Janelia Farm) was cloned and produced as 
described previously (12, 13). Standard ChR2 was used which has been characterised (14) 
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and its efficiency confirmed (12, 15, 16). The conserved AVP promoter comprises a 1.9kb 
sequence has been revealed by BLAT (BLAST-like alignment tool)(16). 
 
Intravitreal virus injection  
Rats were anaesthetised with an intraperitoneal injection (IP) of ketamine (75mg/kg) 
and medetomidine (0.5mg/kg). Once placed in a rotatable stereotaxic frame, a midriatic 
(phenylephrine 0.0054% and tropicamide 0.00028%), local anaesthetic (oxybuprocaine 
hydrochloride 0.4%) and antibiotic (ofloxacin 0.3%) were applied to each eye. The head was 
rotated in the frame and the eye punctured with a fine needle (31G extra short dental cartridge 
needle, 0.28 x 12mm; Terumo, Belgium) connected to a 5-μl Hamilton syringe and the needle 
tip lowered into the vitreous humour using a micromanipulator. Two 1-μl injections of virus 
were carried out on each eye, one on each lateral side. The virus was injected slowly into the 
eye and the needle left in place for 30s before being slowly retracted. The medetomidine 
anaesthesia was then reversed with subcutaneous administration of atipamezole (1mg/kg). 
Rats were left in their home cages for 6-8 weeks before being used for electrophysiology. 
 
In vitro electrophysiology  
Experiments were carried out either at the beginning of the light phase (ZT 2) or at the 
end of the dark phase (ZT 22). From our previous work (5) we anticipated that the amount of 
vasopressin available for activity-dependent release would be maximal at the end of the dark 
phase and minimal at the end of the light phase. Accordingly, we studied cells at the end of 
the dark phase and in the early light phase. Rats subjected to experimental procedures in the 
dark phase were kept in the dark at all times with no light exposure. Rats were lightly 
anaesthetised in isoflurane before being decapitated and the brains quickly removed. A small 
tissue block containing the SCN was cut and immersed in an ice-cold carbogenated N-
methyl-D-glucamine (NMDG)-based aCSF cutting solution (92mM NMDG, 2.5mM KCl, 
1.25mM NaH2PO4, 30mM NaHCO3, 20mM HEPES, 25mM glucose, 2mM thiourea, 5mM Na-
ascorbate, 3mM Na-pyruvate, 0.5mM CaCl2.4H2O and 10mM MgSO4.7H2O; pH 7.35) (17) 
before being sliced into 300-μm sections in partially frozen cutting solution using a vibratome. 
Brain sections were transferred to a continuously carbogenated NMDG-based aCSF cutting 
solution in a water bath at 33°C to recover. After 5-10min, brain sections were transferred to 
a continuously carbogenated HEPES-based aCSF holding solution (92mM NaCl, 2.5mM KCl, 
1.25mM NaH2PO4, 30mM NaHCO3, 20mM HEPES, 25mM glucose, 2mM thiourea, 5mM Na-
ascorbate, 3mM Na-pyruvate, 2mM CaCl2.4H2O and 2mM MgSO4.7H2O) (17) at room 
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temperature (25°C) for at least 1h before recording. Slices were kept in this same holding 
solution throughout the day until needed for recording. Slices were transferred to the patch-
clamp rig recording chamber and continuously perfused with carbogenated aCSF (119mM 
NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 24mM NaHCO3, 12.5mM glucose, 2mM CaCl2.4H2O 
and 2mM MgSO4.7H2O) (17) at 25°C. Cells and eGFP fluorescence were viewed using a 
Zeiss Axioskop 2FS microscope with water immersion objectives and recordings were made 
using pClamp software (Axon Instruments, Molecular Devices, USA). Individual cells were 
recorded from in a cell-attached configuration using glass pipettes filled with recording aCSF 
and a tip resistance of 3-5mΩ. Once the pipette tip was in contact with a cell, a small amount 
of negative pressure was applied to create a seal with a resistance of 20-80mΩ. Only cells in 
the ventrolateral core region of the SCN were recorded from, and identified based on their 
location with respect to the optic chiasm and third ventricle (Fig. 1). SCN core neurons receive 
direct inputs from VP-RGC’s (5). Once a stable seal was achieved, at least 100s of baseline 
activity was recorded. The slices were then optogenetically stimulated for 200 or 500s and 
continuously recorded from. Optogenetic simulation was achieved by delivering pulses (5ms 
pulses; 3s on 2s off) of blue light (470nm; 20Hz; optoflash LED light source, Cairn Research 
Ltd, UK) to the whole slice through the microscope objective. This protocol was selected as 
the secretion of neuropeptides requires a high-frequency, prolonged stimulation pattern (18). 
In some experiments, the vasopressin V1A antagonist (d(CH2)51Tyr(Me)2Arg8)-vasopressin 
(2μM) (19) was applied to the recording solution once the cells had started to respond to 
optogenetic stimulation. This antagonist acts at both the vasopressin V1A receptor as well 
as the oxytocin receptor; however, it is 100 times more selective for the vasopressin V1A 
receptor than the oxytocin receptor (20). For non-virus transfected controls, SCN cells from 
VP-eGFP rats were recorded from and the slices exposed to pulses of blue light just as the 
virus transfected slices were. 
 
Retina Dissection 
To create retina flatmounts, eyes were removed following decapitation and the lens 
and vitreous humour removed by cutting the cornea around the outer edge of the iris. A cut 
was made down each side of the sclera making sure not to cut the retina then the sclera 
prised open and the retina removed; 3-4 incisions were made from the perimeter of the retina 
allowing it to lie flat. On a shaker, the retinas then incubated in heparinised saline for 5min, 
followed by 0.1M PB for 5min and 4% PFA for 5min. Retinas were then stored in 0.1M PB 




All tissue was processed for free-floating immunohistochemistry as described in (5). 
Before immunohistochemistry, retinas were incubated in an enzyme mixture containing 
0.000072% Collagenase (LS005273; Worthington Chemicals, USA) and 0.001% 
Hyaluronidase (LS005475; Worthington Chemicals, USA) in the dark for 30min at room 
temperature with gentle agitation to remove any vitreous humour that may still be attached 
to the retina (21). After enzyme incubation, retinas were washed in 0.1M PB then incubated 
in 0.1M glycine in 0.1M PB for 30 min. After washing, retinas were incubated in blocking 
buffer (10% normal goat serum in 0.1M PB and 0.3% triton-X100) for 1h followed by the 
primary antibodies against GFP (chicken anti-GFP; 1:1000; Abcam ab13970) and mCherry 
(rabbit anti-mCherry; 1:100; ThermoFisher Scientific PA5-34974) in blocking buffer (5% 
normal goat serum in 0.1M PB and 0.3% triton-X100) for 48h at 4°C with gentle agitation. 
Following washes, the retinas were incubated with goat anti-chicken Alexa Fluor 488 
(ThermoFisher Scientific A11039; 1:500) and goat anti-rabbit Alexa Fluor 568 (ThermoFisher 
Scientific A11011; 1:500) secondary antibodies for 80min diluted in 3% normal goat serum, 
0.3% triton-X100 and 0.03% tween in 0.1M PB. The retinas were then mounted onto gelatin-
coated slides and coverslips applied with PermaFlour mounting medium. Retina images were 
taken for analysis using a Leica DMR epifluorescence microscope. Images were processed 
and co-localization of GFP and mCherry immunofluorescence quantified using Fiji software. 
 
Analysis 
All analysis was carried out using ClampFit (Version 10.7, Axon Instruments, 
Molecular Devices, USA), Microsoft Excel and GraphPad Prism 6 software. The spontaneous 
firing of SCN cells was recorded for at least 100s before the slice was optogenetically 
stimulated, and the mean spontaneous firing rate recorded. For each cell firing at > 1 spike/s 
we constructed an interspike interval (ISI) histogram (in 10-ms bins) of spontaneous activity 
from the last 100s of baseline recording (22), and calculated the coefficient of variation (CV) 
as the ratio of the standard deviation/mean ISI. As ISI distributions for slow firing cells were 
all long-tailed with a conspicuous skew, we also calculated the CV from the log ISIs. 
Hazard functions plot how the excitability of a cell evolves with respect to time since 
the last spike (23). These were constructed from the ISI distribution (in 10-ms bins) according 
to the formula (hazard in bin [t, t+ 10]) = (number of ISIs in bin [t, t+10])/(number of ISIs of 
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length > t). These functions were truncated at the bin where the residual number of ISIs was 
< 20. 
To assess responses to optogenetic stimulation, for each cell the % change in firing 
rate was determined from the mean of the last 100s baseline and last 100s during stimulation. 
Only cells that responded with a mean change in firing rate of ≥10% and a firing rate change 
of ≥0.5 spikes/s were considered to be responsive. 
 
Statistical Analysis 
Data were tested for deviations from normality using a D’Agostino & Pearson omnibus 
normality test. For data sets that were too small for meaningful normality testing (200s 
stimulation (n=6), non-parametric statistical tests were used. Larger data sets passed 
normality testing (p>0.05; 500s stimulation (n=12) and VP-GFP cells (n=8)) and parametric 
statistical tests were used. 
Mean baseline firing rates between groups of cells were compared using an unpaired 
two-tailed t-test. For cells tested with the vasopressin V1A receptor antagonist, the effects of 
the antagonist on cells activated by optogenetic stimulation were calculated as the difference 
in firing rate between the last 100 s of optogenetic stimulation and the firing rate in the period 
100-200s after antagonist exposure. These changes were compared with the changes 
measured in cells unresponsive to optogenetic stimulation by an unpaired t-test. Variances 





VP-RGC viral transfection 
Following immunohistochemistry of retina flatmounts, co-localisation of eGFP 
(vasopressin) and mCherry (viral reporter) was quantified. On average 65.4 ± 8.2% (n=4) of 
eGFP expressing VP-RGC’s co-expressed mCherry for each retina (Fig. 1A). In total, 144 
cells out of 243 eGFP+ VP-RGC’s co-expressed mCherry, and only one non-eGFP+ cell 
showed mCherry expression.  
 
Spontaneous activity of ventrolateral SCN cells 
Recordings were made in SCN slices from 13 rats at the beginning of the light phase 
(ZT 2) and from 10 rats recorded at the end of the dark phase (ZT 22). Spontaneous firing 
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rates for ventrolateral SCN cells varied from 0.03 to 16.3 spikes/s with a mean (±SEM) firing 
rate of 4.4 ± 0.4 spikes/s (n=99), similar to rates recorded in previous studies in vitro (24). 
The mean spontaneous firing rate for cells recorded in the light phase (mean 4.5 ± 0.7 
spikes/s, range 0.03 to 16.3 spikes/s, n=50) was similar to that of cells recorded in the dark 
phase (mean 4.4 ± 0.4 spikes/s, range 0.3 to 11.6 spikes/s, n=49). Thus, the spread of firing 
rates was greater for cells recorded in the light phase than for those in the dark phase 
(P<0.001; F test two sample for variances, F=3.4, d.f.48,49). 
The regularity of spike activity can be measured by the coefficient of variation of ISIs: 
a CV value close to 1 is indicative of random firing and a CV value close to 0 is indicative of 
very regular firing. The mean CV was 0.51± 0.04 (n=49) for cells in the dark phase and 
significantly larger (0.77 ± 0.06 n=50) for cells in the light phase (P=0.006). However, the CV 
varies with mean firing rate when ISI distributions are long-tailed, so might reflect the greater 
abundance of slow firing cells in the light phase. If the CV is calculated from the log ISIs it is 
independent of mean firing rate (i.e. there is no significant correlation between the mean rate 
and the CV for log-transformed data); the CV of logISIs was 0.077 ± 0.005 in the dark phase 
and significantly larger at 0.13 ± 0.01 in the light phase (P<0.001) (Fig. 2A). 
To assess firing patterns, ISI histograms were constructed for all cells with a firing rate 
above 1.3 spikes/s. Cells recorded in both the light and dark phases showed a unimodal ISI 
distribution with modes between 60 and 220 ms, depending on mean firing rate. From the ISI 
histograms and CV values it was apparent that cells recorded in the light phase were 
individually more irregular in their spiking (as reflected in the significant difference between 
the CV of logISIs as shown in Fig. 2A). These cells also had a wider range of mean 
spontaneous firing rates (Fig. 2A).  
Hazard functions were constructed from ISI histograms to assess activity-dependent 
influences on excitability in each cell. Cells firing at less than 1.3 spikes/s were excluded from 
hazard function analysis (16 light phase cells and 5 dark phase cells). The individual hazard 
functions shapes for the other 78 ‘active’ cells (firing rate >1.3 spikes/s) were strongly 
dependent on firing rate i.e. speed of inferred repolarisation following a spike (Fig. 2B). We 
split these cells into three groups of 26 on the basis of firing rate and plotted the mean hazard 
function for these groups (Fig. 2B). The fastest firing rate group (mean 8.5 ± 0.8 spikes/s; 
range 6.3-16.3), distinguished by the steepest hazard function plot, contained 16 cells in the 
light phase (Fig. 2C-E) and 10 cells in the dark phase; the middle firing rate group (mean 4.5 
± 0.2 spikes/s; range 3.3-6.3) contained 7 in the light phase and 17 in the dark phase; and 
the slow firing rate group (mean 2.3 ± 0.1 spikes/s; range 1.3-3.2) contained 10 cells in the 
 9 
light phase and 16 in the dark phase (Fig. 2C-E). These hazard functions demonstrate that 
cells recorded in both light and dark phases display a similar range of repolarization speeds. 
 
 
Responses of ventrolateral SCN cells to optogenetic stimulation  
 Fifteen of 50 ventrolateral SCN cells recorded in the light phase and 12 of 49 cells 
recorded in the dark phase responded to optogenetic stimulation with a change in firing rate 
of >10% and at least 0.5 spikes/s. As cells in the dark and light phases had similar baseline 
firing rates and as similar proportions responded to optogenetic stimulation, the responses 
were analysed together. 
 Twenty-one SCN cells were tested with 200s of optogenetic stimulation. Six showed 
increased firing rate throughout stimulation (baseline 6.4 ± 1.1 spikes/s, stimulation 8.8 ± 1.4 
spikes/s; (Fig. 3A,D,E). A large, narrow ISI histogram peak and steep hazard function plot 
can be seen with optogenetic stimulation demonstrating increased firing frequency and faster 
repolarization (Fig. 3B,C). The mean change in firing rate for these six cells was 2.4 ± 0.8 
spikes/s, whereas the mean change in firing rate for the 15 non-responsive cells was -0.4 ± 
0.2 spikes/s (Fig. 3E).  
Forty-three ventrolateral SCN cells were stimulated for 500s and 12 of these showed 
increased firing rate throughout (baseline 2.9 ± 0.9 spikes/s, stimulation 5.2 ± 1.1 spikes/s; 
Fig. 4A,B,C). For these 12 cells, the mean change in firing rate was 2.3 ± 0.5 spikes/s (2.9 ± 
0.9 spikes/s in the 6 cells in the light phase; 1.7 ±0.4 spikes/s in the 6 cells in the dark phase). 
The mean change in firing rate for the 31 non-responsive cells was -0.8 ± 0.4 spikes/s (Fig. 
4C).  
Another two cells responded to optogenetic stimulation with a single burst of increased 
firing rate in the first 100s of stimulation. These two cells were stimulated for 500s and showed 
a change in firing rate of 11.8 and 2.4 spikes/s respectively during the first 100s of stimulation 
only. For these cells, the baseline firing rate was 3.3 ± 0.2 and 7.1 ± 0.3 spikes/s, and the 
firing rate during the first 100s of stimulation was 15.1 ± 1.1 and 9.5 ± 1.0 spikes/s, 
respectively. 
Twelve ventrolateral SCN cells from five non-virus transfected control VP-eGFP rats 
were also recorded at the beginning of the light phase and the slices exposed to 500s of 
pulses of blue light. The mean change in firing rate for these control cells was -0.9 ± 0.4 
spikes/s (Fig. 4C). 
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Effects of a vasopressin V1A receptor antagonist 
During optogenetic stimulation, a vasopressin V1A receptor antagonist was applied to 
27 ventrolateral SCN cells. Before application of the antagonist, seven of these cells had 
responded to optogenetic stimulation with a mean increase in firing rate of 3.7 ± 1.0 spikes/s 
from a basal rate of 7.4 ± 2.1 spikes/s (Fig. 5A-C). During antagonist application, there was 
a reduction in firing rate in each of the seven cells (stimulation 11.6 ± 2.2 spikes/s, 
stimulation/antagonist 9.2 ± 2.3 spikes/s; Fig. 5A-C). By contrast, for the 20 non-responsive 
SCN cells, application of the antagonist had no significant effect on firing rate (baseline 5.6 ± 
0.7 spikes/s, stimulation 5.5 ± 0.6 spikes/s, stimulation with antagonist 5.6 ± 1.1 spikes/s; Fig. 
5C). Thus, during optogenetic stimulation, the antagonist reduced the firing rate of the 7 
responsive cells by 2.3 ± 0.4 spikes/s, whereas in the 20 cells non-responsive to optogenetic 
stimulation it produced a mean increase of 0.1 ± 0.7 spikes/s (significant difference between 
groups, t-test, P=0.003). 
 
Responses of vasopressin expressing SCN cells to optogenetic stimulation 
Eight eGFP+ dorsomedial SCN cells from six virus-transfected rats were recorded 
(Fig. 6A; light phase n=7, dark phase n=1). The spontaneous firing rate of these cells ranged 
from 0.03 to 14.7 spikes/s with a mean of 4.5 ± 2.0 spikes/s. Optogenetic stimulation had no 
excitatory effect on any of these eGFP+ cells, and no significant effect overall on the 
population (baseline 4.5 ± 2.0 spikes/s, stimulation 3.1 ± 1.3 spikes/s; P = 0.11; Fig. 6B,C). 
 
Discussion 
Optogenetic activation of VP-RGC axons terminating in the SCN increased the 
electrical activity of approximately 30% of neurons in the ventrolateral SCN. This appeared 
to be mediated in part by vasopressin as shown by the dampening of stimulation-induced 
responses with the administration of a vasopressin V1A receptor antagonist, consistent with 
the hypothesis that vasopressin is released in an activity-dependent manner from the axons 
of VP-RGCs. No significant effects of the antagonist were seen in any cell that did not respond 
to optogenetic stimulation. 
 The most common response to optogenetic stimulation of VP-RGC axons was an 
increase in firing rate that developed progressively during stimulation and which outlasted 
the stimulation. Such slowly developing and persistent effects are expected of activity-
dependent peptide release (25). RGCs also use glutamate as a neurotransmitter (26). 
However, the expected response to evoked glutamate release is a rapid onset, adapting 
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response during stimulation, locked to the stimulation pattern with prompt termination at the 
end of stimulation, very different in all respects from most of the observed responses, 
although two cells responded with a transient burst of increased firing. It thus appears that, 
generally, the responses to stimulation reported in these experiments were not mediated 
monosynaptically by glutamate release. These responses were however blocked by the 
administration of a vasopressin V1A receptor antagonist. 
SCN cells are heterogeneous in their electrophysiological characteristics. Many SCN 
cells are spontaneously active in vitro; in many of these, each spike is followed by an after-
hyperpolarisation followed by a progressive repolarisation that reaches spike threshold. This 
mechanism gives rise to regular spiking at a frequency determined in part by the magnitude 
and duration of the afterhyperpolarisation. In most other SCN cells, there is again a 
repolarisation following an afterhyperpolarisation, but the repolarisation does not exceed 
spike threshold and so spike timing in these cells is more irregular, presumably dominated 
by the random arrival of synaptic input. Thus Pennartz et al. reported that most SCN cells 
could be classified as Cluster I and II cells that fired spontaneously in a regular and irregular 
mode respectively (24). The afterhyperpolarisation in cluster I cells is supported by at least 
three subtypes of K(Ca) channels, including apamin-sensitive channels and iberiotoxin-
sensitive channels; these channels are subject to diurnal modulation by the circadian clock 
leading to the expression of a circadian rhythm in spiking frequency (27). 
Pennartz et al. observed the after-hyperpolarisations directly by patch-clamp 
recordings: in the present study used cell-attached recordings to avoid any disruption of the 
intracellular milieu (24).  We noted that spike activity in virtually all SCN neurons was 
relatively regular, with a CV of less than 1 (which would be indicative of purely random firing), 
and often very much less than 1 (indicative of very regular firing). However, we could not 
objectively separate two populations based on this alone. The sequence of 
afterhyperpolarisation and repolarisation in a spontaneously active cell is reflected in the 
hazard function, and again we noted that whereas some cells showed an early onset of 
repolarisation, in many others it was markedly delayed, consistent with a prolonged 
afterhyperpolarisation. However, we could not objectively separate two populations based on 
this, nor did we find any evidence that responsiveness to optogenetic stimulation was 
associated with any observed difference in cell properties. 
 There is considerable evidence for circadian regulation of potassium currents in the 
SCN (28, 29), so, in the present study, we recorded SCN cells at the end of the dark phase 
and at the beginning of the light phase. We observed no significant differences in the mean 
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spontaneous firing, rate but cells in the light phase showed a wider range of spontaneous 
firing rates, and also fired less regularly. This is partly consistent with a change in their 
intrinsic activity-dependent properties; a reduction in the magnitude of the 
afterhyperpolarisation would be expected to produce both higher firing rates and increased 
irregularity of firing, but this would not explain why we also saw more slow firing cells in the 
light phase.  
 We did not biochemically identify the cells recorded in the ventrolateral SCN, but the 
recording sites are consistent with the distribution VIP and GRP cells in the rat SCN (30). VIP 
and GRP neurons are part of a complex network within the SCN signalling to other cell types 
in the dorsomedial SCN to generate rhythms of neuronal activity (31, 32), which are crucial 
to the functioning and output of the SCN (2). We have previously shown that VP-RGC axons 
terminate in this region and make close synaptic contacts with both VIP- and GRP-expressing 
neurons (5). 
 The shell region of the SCN contains many vasopressin neurons that might also be a 
source of vasopressin release following optogenetic stimulation. These neurons are primarily 
situated in the dorsomedial SCN (30) and we have previously shown that VP-RGC axons do 
not make direct contacts with these vasopressin cells (5). The small population of 
dorsomedial SCN vasopressin cells (eGFP+) that we recorded from did not respond to 
optogenetic stimulation. Magnocellular vasopressin neurons are also known to secrete 
vasopressin from their dendrites in an activity-independent manner (33). Therefore, even in 
the absence of increased electrical activity, it is possible that these neurons secrete 
vasopressin into the SCN. 
  In conclusion, the present study provides evidence for communication between VP-
RGCs and ventrolateral SCN neurons, supporting the idea that VP-RGCs play an important 
role in the regulation of the SCN. Various studies have shown that vasopressin is involved in 
the maintenance and prevention of the maladaptive shifting of circadian rhythms (6, 8, 9). As 
the disruption of circadian rhythms in humans is associated with a whole variety of diseases 
and conditions including obesity, cardiovascular disease, depression and cognitive 
impairment (3, 34-36), there is great interest in understanding the mechanisms underlying 
circadian dysfunction to identify potential therapeutic targets.  
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Figure 1) The spatial distribution of ventrolateral SCN cells responding to 
optogenetic stimulation of VP-RGC axons and viral reporter expression in the retina. 
A) The sites of responding ventrolateral SCN cells recorded in brain slices. B) Diagrams 
indicating the position of each responding cell recorded mapped onto the rat brain atlas at 
bregma -0.06/0.72mm and -0.84/0.96mm. White shapes represent cells showing overall 
increase in firing rate, grey shapes represent cells showing an initial burst of increased firing, 
and black shapes represent cells whose responses were attenuated by application of a 
vasopressin V1A receptor antagonist. Circles = recordings from ZT2, squares = ZT22. DL, 
dorsomedial; OC, optic chiasm; VM, ventrolateral; 3V, third ventricle. C) Viral reporter 
expression in VP-RGC’s in retina flat mounts focused on the retinal ganglion cell layer. 
Immunohistochemistry for eGFP shown in green, immunohistochemistry for mCherry (viral 
reporter) shown in red and co-localisation of the two shown in yellow. Arrows point to VP-
RGC’s expressing mCherry.  
 
Figure 2. Spontaneous activity of SCN cells  
A) CV of log ISI plotted against mean log ISI for all spontaneously active SCN cells firing at 
>1.3 spikes/s. Open symbols: cells recorded in the light phase; closed symbols: cells 
recorded in the dark phase. The large symbols are cells activated by optogenetic stimulation, 
the small symbols are cells unresponsive to stimulation. B) Mean (±S.E.) hazard functions of 
SCN light and dark phase neurons in 10-ms bins constructed from 100 s of spontaneous 
activity. Hazard functions were constructed only for the 78 cells firing at >1.3 spike/s. The 
cells were separated into three groups of 26 cells by their mean firing rate. The fast firing 
cells (triangles) fired at a mean rate of 8.5 ± 0.8 spikes/s, the middle group (open circles) at 
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4.5 ± 0.2 spikes/s and the slow cells (closed circles) at 2.3 ± 0.1 spikes/s. C) Extracts of the 
raw spike traces for a representative light-phase cell with a fast repolarization (left panel) and 
dark-phase cell with a slow repolarization (right panel). D) ISI histograms for the two cells 
shown in B and E) corresponding hazard functions.  
 
Figure 3. Responses of SCN cells to 200s optogenetic stimulation.  
A) Example of an SCN cell showing excitation during 200s of optogenetic stimulation (grey 
background). B) ISI distributions for the 100-s before stimulation (closed circles) and during 
the 200 s of stimulation (open circles). The functions are normalised to the total number of 
spikes, so the Incidence plotted is the % of spikes in each 10-ms bin. C) Hazard functions 
corresponding to the ISI distributions in B. D) Change in firing rate over time (spikes/s, in 25 
s bins; mean ± SEM) for 6 responding cells. Circles = recordings from ZT2, squares = ZT22 
E) Mean (±S.E.) change in firing rate for the 6 responsive cells (red) and 15 non-responding 
cells (blue) during 200 s of optogenetic stimulation and over the subsequent 200s. 
 
 
Figure 4) Responses of SCN cells to 500s optogenetic stimulation.  
A) Example of SCN cell activated throughout 500s of optogenetic stimulation (grey 
background). B) Firing rate before stimulation and during the last 100s of stimulation for 12 
responding cells. Circles = recordings from ZT2, squares = ZT22. C) Mean ± SE change in 
firing rate during optogenetic stimulation for 500s (grey background) for 12 responding cells 
(red), 32 non-responding cells (orange) and 12 SCN cells from non-virus transfected control 
rats (blue). 
 
Figure 5) A vasopressin V1A antagonist reduces response to optogenetic 
stimulation.  
A) Example of SCN cell responding to optogenetic stimulation (light grey background) and 
application of a vasopressin V1A antagonist (dark grey background). B) Mean firing rate 
(spikes/s; 100s) for baseline, optogenetic stimulation and stimulation in the presence of the 
antagonist for 7 cells responding to optogenetic stimulation. Circles = recordings from ZT2, 
squares = ZT22. C) Mean ± SE change in firing rate (spikes/s; 100s) during stimulation, 
stimulation in the presence of the antagonist and recovery for 7 stimulation responding cells 
and 20 stimulation non-responding cells.  
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Figure 6) SCN vasopressin cells did not respond to optogenetic stimulation  
A) Representative image of SCN dorsomedial eGFP+ cell recorded. B) Example of SCN 
recording from eGFP positive cell with optogenetic stimulation (grey background). C) Mean 
± SEM change in firing rate during 300s of stimulation (n=8). 
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